Study of Capecitabine and Cyclophosphamide Administered as a Single Pill in Patients with Advanced Breast Cancer
- Conditions
- Health Condition 1: null- Breast CancerHealth Condition 2: C509- Malignant neoplasm of breast of unspecified site
- Registration Number
- CTRI/2016/01/006485
- Lead Sponsor
- SanofiSynthelabo India Private Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 54
Female >= 18 and <= 65 years old
2. Patients with histologically or cytologically confirmed Metastatic Breast Cancer (HER2 negative, ER/PR positive or negative), who are candidates to receive capecitabine and cyclophosphamide as per investigatorâ??s judgment, and meet either one of the following characteristics:
a. Recurrence of the disease following at least 2 lines of chemotherapy failure for metastatic triple negative breast cancer
b. In ER/PR positive breast cancer, recurrence of the disease following at least 1 line of chemotherapy failure and 2 lines of hormonal therapy failure
3. Patients who have been previously treated with capecitabine can be recruited in the study provided :
a) As per the Investigatorâ??s opinion, patients will benefit from this chemotherapy AND
b) For prior single administration of capecitabine: at least 6 months has elapsed between last capecitabine treatment and initiation of study treatment.
c) For prior capecitabine-based combination regimen: at least 12 months has elapsed between last capecitabine-based treatment and initiation of study treatment.
4. At least one uni-dimensionally measurable lesion according to RECIST criteria version 1.1
5. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2
6. Life expectancy of >3 months,
7. Patients who are willing to undergo (oral) chemotherapy for the treatment of their disease and who are expected to comply with the treatment and study procedures, as per the Investigatorâ??s judgment
8. For women of child bearing potential, documented negative pregnancy test and agreement to use acceptable birth control measures during the duration of the study therapy
9. Signed Informed consent obtained prior to any study related procedures
1. Patients who are HER 2 positive
2. Patients with 3 or more lines of chemotherapy failure for metastatic triple negative breast cancer
3. In ER/PR positive breast cancer, recurrence of the disease following 2 or more lines of chemotherapy failure and/or 3 or more lines of hormonal therapy failure
4. Patients presenting with de novo stage IV metastatic breast
cancer, not previously treated for their disease
5. Patients who have already received any metronomic chemotherapy regimen
6. Known hypersensitivity to capecitabine or to any of its components
7. Known hypersensitivity to 5-fluorouracil
8. Known hypersensitivity to cyclophosphamide or any of its components
9. History of bladder carcinoma
10. Systemic anticancer therapy (chemotherapy, hormone therapy or radiotherapy) within 4 weeks of randomization for the study
11. History of unexplained hematuria
12. History of dihydropyrimidine dehydrogenase (DPD) deficiency
13. Severe renal impairment (creatinine clearance below 30 mL/min [Cockroft and Gault])
14. Concomitant warfarin treatment
15. History of significant cardiac disease (e.g. unstable angina, congestive heart failure, myocardial infarction, ventricular arrhythmias) within the previous 6 months
16. Conditions/situations such as:
a. Patient is the Investigator or any Sub-Investigator, research assistant, pharmacist, Study co-ordinator, other staff, or relative thereof, directly involved in the conduct of the protocol
b. Uncooperative Patient or any condition that could make the Patient potentially non-compliant to the study procedures
17. Pregnant or breast-feeding women
18. Women of childbearing potential not protected by effective contraceptive method of birth control and/or who are unwilling or unable to be tested for pregnancy.
19. Patients with a possibility of active tuberculosis as suggested by:
a. Any signs or symptoms suggestive of active tuberculosis upon medical history or clinical examination
b. Chest radiograph within 3 months prior to the screening visit consistent with tuberculosis infection
c. Patients with close contact with a person with active tuberculosis
20. Known history of Human Immunodeficiency Virus (HIV)
21. Any other significant medical conditions which in the judgment of the Investigator would preclude completion of the study
22. Participation in a clinical research study evaluating another
investigational drug or therapy within 30 days prior to the Screening Visit 23. Presence of any of the following laboratory abnormalities at the Screening Visit:
a. Hemoglobin 8.5g/L
b. WBC 3000/μL;
c. platelet count 100 000/μL;
d. Absolute neutrophil count (ANC) 1500/μL;
e. AST or ALT 1.5 x ULN (or 5 x ULN in patients with liver metastasis)
f. Total Bilirubin 1.5 X ULN (or 2 x ULN in patients with liver metastasis)
24. Patients with a body surface area (BSA) 1.0 m² or1.8 m²
Total expected number of patients
36-54 patients
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method